PRESS RELEASE published on 08/15/2025 at 15:21, 5 months 19 days ago enVVeno Medical to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech enVVeno Medical Corporation to present at Webull Financial Corporate Connect Webinar Series: Biotech/MedTech on August 21, 2025, with CEO Robert Berman discussing innovative treatment solutions for deep venous disease Webinar EnVVeno Medical Corporation Bioprosthetic Solutions Deep Venous Disease Webull Financial
BRIEF published on 08/06/2025 at 14:35, 5 months 28 days ago VenoValve d'enVVeno Medical : une solution rentable pour les IVC sévères EnVVeno Medical Insuffisance Veineuse Chronique Approbation De La FDA Économies Sur Les Coûts Des Soins De Santé Valve VenoValve
BRIEF published on 08/06/2025 at 14:35, 5 months 28 days ago EnVVeno Medical's VenoValve: A Cost-Effective Solution for Severe CVI FDA Approval EnVVeno Medical VenoValve Chronic Venous Insufficiency Healthcare Cost Savings
PRESS RELEASE published on 08/06/2025 at 14:30, 5 months 28 days ago Health Economic Study Shows That enVVeno Medical's VenoValve(R) Would be a Cost-Effective Treatment Option for Patients with Severe Chronic Venous Insufficiency Preliminary findings show VenoValve as cost-effective & clinically beneficial for severe CVI. Webcast discussing results. Potential $5.9B annual healthcare savings. Study shows cost savings and clinical benefits Webcast VenoValve Healthcare Savings CVI Cost-Effectiveness
BRIEF published on 08/04/2025 at 15:10, 5 months 30 days ago EnVVeno Medical Explores Potential Impact of Trump's CVI Diagnosis on Treatment Options FDA Approval VenoValve CVI Diagnosis Trump Impact Healthcare Cost
BRIEF published on 08/04/2025 at 15:10, 5 months 30 days ago EnVVeno Medical étudie l'impact potentiel du diagnostic d'IVC de Trump sur les options de traitement. Approbation De La FDA Valve VenoValve Diagnostic De L'IVC L'impact De Trump Coût Des Soins De Santé
PRESS RELEASE published on 08/04/2025 at 15:05, 5 months 30 days ago enVVeno Medical Participates in a New Virtual Investor "What This Means" Segment to Discuss How President Trump's Recent CVI Diagnosis May Impact the Company enVVeno Medical is developing the VenoValve as a potential treatment for Chronic Venous Insufficiency. FDA decision expected in 2H'2025 EnVVeno Medical VenoValve Chronic Venous Insufficiency FDA Decision Deep Venous Disease
BRIEF published on 08/01/2025 at 14:05, 6 months 2 days ago EnVVeno Medical Q2 2025 Financial Report and Corporate Update EnVVeno Medical VenoValve Q2 2025 Results EnVVe Progress FDA Decision
BRIEF published on 08/01/2025 at 14:05, 6 months 2 days ago Rapport financier et mise à jour de l'entreprise d'enVVeno Medical pour le deuxième trimestre 2025 EnVVeno Medical Valve VenoValve Résultats Du Deuxième Trimestre 2025 Progrès EnVVe Décision De La FDA
PRESS RELEASE published on 08/01/2025 at 14:00, 6 months 2 days ago enVVeno Medical Reports Second Quarter 2025 Financial Results and Provides Corporate Update enVVeno Medical reports $3.8M cash burn & financial results for Q2 2025. Operations funded through Q3'2026 with sufficient cash. FDA decisions & clinical program progress on track Financial Results EnVVeno Medical Cash Burn FDA Decisions Clinical Program Progress
Published on 02/04/2026 at 02:15, 3 hours 12 minutes ago Future Fuels Announces $2 Million LIFE Flow-Through Offering
Published on 02/04/2026 at 00:00, 5 hours 27 minutes ago Sintana Energy Inc. Announces VMM-37 Resolution
Published on 02/03/2026 at 23:30, 5 hours 57 minutes ago FutureGen Industries Retains Market-Making Services
Published on 02/03/2026 at 23:12, 6 hours 15 minutes ago Appointment of Credit Advisor for Stage 1 Operations
Published on 02/03/2026 at 22:30, 6 hours 57 minutes ago Green Bridge Announces Closing of Non-Brokered Private Placement for Gross Proceeds of C$4 Million
Published on 02/04/2026 at 02:05, 3 hours 22 minutes ago Saudi Arabia Preparing for AlUla Emerging Market Economies Conference to be Held February 8-9, 2026
Published on 02/04/2026 at 00:42, 4 hours 45 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: Appendix 3X - Initial Director's Interest Notice
Published on 02/03/2026 at 20:57, 8 hours 30 minutes ago EQS-Adhoc: tick Trading Software AG adjusts forecast for the current 2025/2026 fiscal year
Published on 02/03/2026 at 20:36, 8 hours 51 minutes ago Freelance.com: Agenda de communication financière 2026-2027
Published on 02/03/2026 at 20:05, 9 hours 22 minutes ago KHUFU'S IN EGYPT NAMED NO.1 AT MIDDLE EAST & NORTH AFRICA'S 50 BEST RESTAURANTS 2026
Published on 02/03/2026 at 18:00, 11 hours 27 minutes ago Mint dépasse ses ambitions annoncées pour 2025 grâce à des succès commerciaux majeurs dans le BtoB
Published on 02/03/2026 at 17:45, 11 hours 42 minutes ago Informations relatives au nombre total de droits de vote et d’actions
Published on 02/03/2026 at 17:45, 11 hours 42 minutes ago Chiffre d’affaires 2025 en croissance à 11,2 M€ (+5%)